De Sarro G, Di Paola E D, Aguglia U, de Sarro A
Department of Experimental Medicine, School of Medicine, Catanzaro, Italy.
Pharmacol Biochem Behav. 1996 Sep;55(1):39-48. doi: 10.1016/0091-3057(96)00062-7.
The development of tolerance to the anticonvulsant effects of clonazepam, clobazam, and diazepam were studied in genetically epilepsy-prone rats following intraperitoneal (IP) or oral administration. The anticonvulsant effects were evaluated on seizures evoked by means of auditory stimulation (109 dB, 12-16 kHz). All compounds showed 60 min after IP injection antiseizure activity with ED50 against clonus of 0.24 mumol kg-1 for clonazepam, 0.72 mumol kg-1 for diazepam, and 3.9 mumol kg-1 for clobazam. After 120 min of oral administration the ED50 against clonus of 2.37 mumol kg-1 for clonazepam, 15.8 mumol kg-1 for diazepam, and 30 mumol kg-1 for clobazam. The dose chosen for the chronic treatment were 2.5 mumol kg-1 for clonazepam, 15 mumol kg-1 for diazepam, and 30 mumol kg-1 for clobazam. The animals were treated three times daily for 4 or 6 weeks. Auditory stimulation was administered 60 min after drug IP injection on various days. During treatment, tolerance was observed as a loss of drug anticonvulsant effects. No changes of occurrence of audiogenic seizures was observed in rats treated with vehicle. Tolerance to the anticonvulsant activity developed most rapidly during clobazam treatment, less rapidly following diazepam treatment, and most slowly during clonazepam treatment. Sixty minutes after IP injection on various days of chronic treatment the motor impairment induced by these benzodiazepines was also studied by means of a rotarod apparatus. The tolerance to the motor impairment developed more rapidly than the anticonvulsant effects. The response to auditory stimulation to benzodiazepines was stopped 24 and 48 h after chronic treatment with these compounds, showing no residual drug effects and that rats were still tolerant. The genetically epilepsy-prone rats is a reliable and sensitive model for studying long-term effects of anticonvulsant drugs.
在腹腔注射(IP)或口服给药后,研究了遗传性癫痫易感性大鼠对氯硝西泮、氯巴占和地西泮抗惊厥作用的耐受性。通过听觉刺激(109分贝,12 - 16千赫)诱发癫痫发作来评估抗惊厥作用。所有化合物在腹腔注射后60分钟均显示出抗癫痫活性,氯硝西泮对阵挛的半数有效量(ED50)为0.24微摩尔/千克,地西泮为0.72微摩尔/千克,氯巴占为3.9微摩尔/千克。口服给药120分钟后,氯硝西泮对阵挛的ED50为2.37微摩尔/千克,地西泮为15.8微摩尔/千克,氯巴占为30微摩尔/千克。慢性治疗选用的剂量为氯硝西泮2.5微摩尔/千克,地西泮15微摩尔/千克,氯巴占30微摩尔/千克。动物每天接受三次治疗,持续4或6周。在不同日期腹腔注射药物后60分钟给予听觉刺激。在治疗期间,观察到耐受性表现为药物抗惊厥作用的丧失。用赋形剂处理的大鼠未观察到听源性癫痫发作发生率的变化。对氯巴占治疗期间抗惊厥活性的耐受性发展最快,地西泮治疗后较慢,氯硝西泮治疗期间最慢。在慢性治疗的不同日期腹腔注射后60分钟,还通过转棒仪研究了这些苯二氮䓬类药物引起的运动障碍。对运动障碍的耐受性比对抗惊厥作用发展得更快。在用这些化合物进行慢性治疗后24小时和48小时,对苯二氮䓬类药物的听觉刺激反应停止,表明没有残留药物作用且大鼠仍有耐受性。遗传性癫痫易感性大鼠是研究抗惊厥药物长期作用的可靠且敏感的模型。